Trial · NCT00490698
Zoledronate With Atorvastatin in Renal Cell Carcinoma
NCT00490698, Phase 2, Completed, M.D. Anderson Cancer Center; results first posted 2013-03-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zoledronate With Atorvastatin in Renal Cell Carcinoma. Trials, record NCT00490698. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00490698
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zoledronate With Atorvastatin in Renal Cell Carcinoma
- NCT number
- NCT00490698
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 11 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Kidney Cancer, Renal Cell Carcinoma
- Interventions
- Zoledronate, Atorvastatin
- First posted
- 2007-06-25
- Last updated
- 2013-03-18
- Results first posted
- 2013-03-18
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Median Time to First Skeletal-related Event | Up to 1 year | Time to skeletal events, defined as a metastatic site requiring radiotherapy or any surgical intervention (eg, embolization, radiofrequency ablation, intrathecal catheter placement) or complications from skeletal metastatic lesions (eg, pathologic fracture, spinal cord compression). Time to skeletal events monitored every 8 weeks for at least 1 year. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Median Time to First Skeletal-related Event | Up to 1 year | Four participants did not experience skeletal events. | months | MEDIAN |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Median Time to First Skeletal-related Event | Zoledronate + Atorvastatin | 9 | 95% Confidence Interval 4.1 to 18.1 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Zoledronate + Atorvastatin | 11 | |
| Overall Study | COMPLETED | Zoledronate + Atorvastatin | 1 | |
| Overall Study | NOT COMPLETED | Zoledronate + Atorvastatin | 10 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Desquamatory rash | Skin and subcutaneous tissue disorders | Zoledronate + Atorvastatin | 1 | 11 | |
| other | Fever | Infections and infestations | Zoledronate + Atorvastatin | 1 | 11 | |
| other | Fatigue | General disorders | Zoledronate + Atorvastatin | 11 | 11 | |
| other | Lymphopenia | Blood and lymphatic system disorders | Zoledronate + Atorvastatin | 1 | 11 | |
| serious | Transient ischemic attack | Blood and lymphatic system disorders | Zoledronate + Atorvastatin | 1 | 11 | |
| serious | Bone Pain | Musculoskeletal and connective tissue disorders | Zoledronate + Atorvastatin | 1 | 11 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Zoledronate + Atorvastatin | ||
| Total, other adverse events | Zoledronate + Atorvastatin | 11 | 11 |
| Total, serious adverse events | Zoledronate + Atorvastatin | 2 | 11 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21958521 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00490698
GET https://conductscience.org/api/trials/v1/NCT00490698/registered